A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function

ClinicalTrials.gov ID: NCT00421044

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00421044. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Patients who participated in the core EPO2121 study and did not clinically progress may participate in this extension protocol to further evaluate the safety, tolerability, and efficacy of patupilone.

Study identification

NCT ID: NCT00421044
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Novartis Pharmaceuticals; Industry
Enrollment: 14 participants

Conditions and interventions

Conditions

Interventions

Patupilone/EPO906 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 2006 (Type not available)
Primary completion: Feb 2008 (Actual)
Completion: Not listed
Last update posted: Jan 11, 2012

Started 2006

United States locations

U.S. sites: 3
U.S. states: 2
U.S. cities: 2

Facility	City	State	ZIP	Site status
University of California San Diego/Moores Cancer Center	La Jolla	California	92093-0987	—
Institute for Drug Development Cancer Therapy & Research Center/The University of Texas Health Science Center	San Antonio	Texas	78229	—
South Texas Accelerated Research Therapeutics	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00421044, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 11, 2012 · Synced Nov 15, 2026